Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. It offers five-in-one whole blood respiratory pathogen Immunoglobulin M, three-in-one combined testing of influenza Immunoglobulin M, and five-in-one combined testing of serum respiratory viruses Immunoglobulin M. It also provides prenatal and postnatal care testing products, automatic colloidal gold immunochromatography analyzers, and automatic blood cell analysis pre-sample processors. The company was founded by Xiu Jie Zhang on February 6, 2006 and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company